Munjack D J, Baltazar P L, Bohn P B, Cabe D D, Appleton A A
Department of Psychiatry, University of Southern California, Los Angeles.
J Clin Psychiatry. 1990 May;51 Suppl:35-40; discussion 50-3.
Twenty-three patients who met DSM-III-R criteria for social phobia were randomly assigned either to a clonazepam treatment group or to a nontreatment control group in an 8-week pilot study. Clonazepam was found to have a significant effect on the treated patients, as demonstrated by scores on a variety of instruments measuring overall anxiety and phobic avoidance, and social phobic symptoms. Initial sedation, which was experienced by 70% of the treated subjects, was the most common side effect of clonazepam treatment and usually resolved spontaneously or with dose reduction. The preliminary findings of this pilot study are sufficiently promising to warrant further study of the efficacy of clonazepam in this condition.
在一项为期8周的初步研究中，23名符合《精神疾病诊断与统计手册第三版修订版》（DSM-III-R）社交恐惧症标准的患者被随机分配到氯硝西泮治疗组或非治疗对照组。通过各种测量总体焦虑、恐惧回避和社交恐惧症状的量表得分表明，氯硝西泮对接受治疗的患者有显著效果。70%的接受治疗的受试者出现了初始镇静作用，这是氯硝西泮治疗最常见的副作用，通常会自行缓解或通过减少剂量缓解。这项初步研究的初步结果很有前景，足以保证对氯硝西泮在这种病症中的疗效进行进一步研究。
